FY 2019 sales trump expectations, EBIT guidance upgraded
22/01/20 -"Galenica reported FY 19 sales of CHF 3.3bn, +4.3%, with broad-based growth across segments – services +2.9% to CHF 2.4bn and ‘health & beauty’ segment, +6.3%, to CHF 1.6bn. Management now ..."
Pages
48
Language
English
Published on
22/01/20
You may also be interested by these reports :
31/10/25
Avolta’s Q3 results slightly missed consensus expectations. While growth was robust across all regions, North America continued to experience some ...
30/10/25
Galenica’s YTD 2025 sales reached CHF 2,999.7 million, growing by 4.7%. This growth was driven by strong tailwinds from prescription drugs, ...
29/10/25
3Q25: Adj. EBITDA exceeded expectations – Confirmed FY25E guidance
16/10/25
Travis Perkins’ Q3 FY25 results showed 1.8% yoy lfl sales growth, slightly beating market expectations, driven by gains in merchanting and ...